Michael F. Press

Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions

Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction

Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers

721MO Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors

Impact of CCND1 amplification on the prognosis of hormone receptor–positive, HER2-negative breast cancer patients—correlation of clinical and pathological markers

Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry

A careful reassessment of anthracycline use in curable breast cancer

Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women

Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)

Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium

A functionally significant SNP in TP53 and breast cancer risk in African-American women

Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry

Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer